HC Wainwright Increases Sana Biotechnology (NASDAQ:SANA) Price Target to $11.00

Sana Biotechnology (NASDAQ:SANA) had its price target hoisted by analysts at HC Wainwright from $8.00 to $11.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 155.81% from the company’s current price.

SANA has been the topic of a number of other reports. TD Cowen upgraded shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research report on Wednesday. JMP Securities lowered shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $14.25.

Sana Biotechnology Price Performance

Shares of NASDAQ SANA opened at $4.30 on Wednesday. Sana Biotechnology has a fifty-two week low of $1.52 and a fifty-two week high of $12.00. The firm has a market capitalization of $960.06 million, a P/E ratio of -3.07 and a beta of 1.45. The company’s 50 day simple moving average is $2.40 and its 200 day simple moving average is $4.07.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.01. Sell-side analysts expect that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Sana Biotechnology

Several institutional investors and hedge funds have recently modified their holdings of the business. Wilmington Savings Fund Society FSB bought a new position in Sana Biotechnology in the third quarter valued at approximately $29,000. Stifel Financial Corp bought a new stake in Sana Biotechnology in the 3rd quarter valued at $43,000. EP Wealth Advisors LLC acquired a new position in Sana Biotechnology in the 3rd quarter worth $45,000. Blue Trust Inc. raised its stake in shares of Sana Biotechnology by 1,246.6% in the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock valued at $55,000 after purchasing an additional 12,154 shares during the period. Finally, Algert Global LLC bought a new stake in shares of Sana Biotechnology in the second quarter valued at about $73,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.